Quintiles Transitional Holdings (Q) 63.32 $Q
Quintiles Introduces Continuous Glucose Monitoring Services to Improve Diabetes Outcomes
BusinessWire - Fri Jun 24, 5:45AM CDT
Quintiles today announced the launch of its new Continuous Glucose Monitoring (CGM) service offering. This new solution combines innovative, wearable technology with Quintiles' deep therapeutic and analytical expertise to help enhance the efficiency and quality of diabetes-focused clinical trials.
Q: 63.32 (-1.70)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces a Class Action has Been Commenced Challenging the Fairness of the Sale of IMS Health Holdings, Inc. to Quintiles Transnational Holdings, Inc. -- IMS
GlobeNewswire - Fri Jun 17, 9:19AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
Quintiles CEO to Present at Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 5:45AM CDT
Quintiles CEO Tom Pike will present at the Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 in New York City at the Grand Hyatt New York.
Q: 63.32 (-1.70)
Why These Stocks are Under the Investor Community's Microscope? - Bruker, Quintiles Transnational Holdings, iKang Healthcare Group, and TrovaGene
PR Newswire - Wed Jun 01, 7:20AM CDT
In today's pre-market research, ActiveWallSt.com has selected the following Medical Laboratories and Research stocks for your evaluation: Bruker Corp. (NASDAQ: BRKR), Quintiles Transnational Holdings Inc. (NYSE: Q), iKang Healthcare Group Inc. (NASDAQ: KANG), and TrovaGene Inc. (NASDAQ: TROV). Access these equities free technical alerts at:
Q: 63.32 (-1.70), TROV: 4.55 (-0.25), KANG: 18.98 (-0.31), BRKR: 22.90 (-1.50)
Quintiles Introduces Precision Enrollment to Enhance Patient Recruitment in Oncology Trials
BusinessWire - Tue May 31, 5:45AM CDT
Quintiles, the world's largest provider of product development and integrated healthcare services, today announced its Precision Enrollment offering. The new enrollment model is designed to significantly accelerate site start-up and patient recruitment in oncology clinical trials working with the company's network of investigative sites across the U.S and leveraging secondary data (e.g. electronic health records-EHRs.) In this new model, the traditional site start-up pathway is realigned so a site is only opened after a patient is identified.
Q: 63.32 (-1.70)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of IMS Health Holdings, Inc. to Quintiles Transnational Holdings, Inc.
BusinessWire - Thu May 26, 2:06PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Into the Fairness of the Sale of IMS Health Holdings, Inc. to Quintiles Transnational Holdings, Inc.
BusinessWire - Mon May 23, 4:04PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
IMS HEALTH HOLDINGS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Quintiles Transnational Holdings, Inc.
BusinessWire - Thu May 05, 10:00AM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of IMS Health Holdings, Inc. ("IMS"
(NYSE: IMS) concerning the sale to Quintiles Transnational Holdings, Inc. (NYSE: Q). Under the terms of the agreement, IMS shareholders will only receive 0.3840 Quintiles shares for each IMS share owned. Based on the closing price of Quintiles before the deal was announced, the consideration is valued at $26.53 per share, which is virtually no premium over the 52-week high and lower than at least one analyst's estimated value of $35.00 per share.
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
IMS HEALTH HOLDINGS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
BusinessWire - Wed May 04, 3:40PM CDT
Rigrodsky & Long, P.A.:
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation as to Whether the Sale of IMS Health Holdings, Inc. to Quintiles Transnational Holdings, Inc. is Fair to Shareholders -- IMS
PR Newswire - Wed May 04, 10:54AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
IMS Health and Quintiles merging in $9 billion stock deal
AP - Tue May 03, 2:26PM CDT
NEW YORK (AP) — Health care data company IMS Health and Quintiles, which helps drug companies with clinical trial research, said Tuesday they are merging in an all-stock deal worth nearly $9 billion.
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
Robbins Arroyo LLP: Combination of IMS Health Holdings, Inc. (IMS) with Quintiles Transnational Holdings Inc. (Q) May Not Be in Shareholders' Best Interests
BusinessWire - Tue May 03, 2:15PM CDT
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed combination of IMS Health Holdings, Inc. (NYSE: IMS) with Quintiles Transnational Holdings Inc. (NYSE: Q). On May 3, 2016, the two companies announced the signing of a definitive merger agreement pursuant to which Quintiles will merge with IMS in an all-stock merger of equals transaction. Under the terms of the agreement, IMS shareholders will receive 0.384 shares of Quintiles for each share of IMS they own, the value of which is equivalent to $26.53 per share of IMS.
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
IMS Health and Quintiles to Merge; Quintiles IMS to Become Industry-Leading Information and Technology-Enabled Healthcare Service Provider
BusinessWire - Tue May 03, 5:00AM CDT
--Broad range of healthcare information, technology and services solutions to drive efficiencies and insights across the entire life sciences product lifecycle, from R&D through commercial execution to real-world patient outcomes.
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
IMS Health and Quintiles to Merge
BusinessWire - Tue May 03, 5:00AM CDT
--All-Stock Transaction with Combined 2015 Revenue of $7.2 Billion and Combined Equity Market Capitalization of $17.6 Billion
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
Novogen Provides Update On Development Of Cantrixil
PR Newswire - Mon May 02, 6:00AM CDT
US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today provided an update on progress regarding the development of Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) molecule, which is intended for the treatment of ovarian cancer.
Q: 63.32 (-1.70), NVGN: 1.92 (-0.07)
Quintiles Receives Technology Security Award from IDG's CSO Magazine for Fourth Consecutive Year
BusinessWire - Fri Apr 22, 5:45AM CDT
Quintiles, the world's leading provider of biopharmaceutical services, announced today that it has been named to the 2016 CSO50 by IDG's CSO magazine. This award recognizes the company's innovative identity management solution designed to expedite activities related to the delivery of clinical trials while simultaneously protecting confidential user data. This is the company's fourth consecutive year receiving the prestigious security award.
Q: 63.32 (-1.70)
Quintiles' First Quarter 2016 Earnings Call Scheduled for Tuesday, May 3rd
BusinessWire - Mon Apr 18, 4:00PM CDT
Quintiles Transnational Holdings Inc. (NYSE: Q) will release its first quarter 2016 financial results Tuesday, May 3, 2016 prior to its quarterly earnings call at 8:00 a.m. EDT.
Q: 63.32 (-1.70)
Quintiles Honored as 'Best CRO in Asia' for Fourth Time in Six Years
BusinessWire - Wed Mar 23, 6:00PM CDT
Quintiles last night was named the "Best CRO in Asia" at the 2016 BioPharma Asia Industry Awards, winning the honor for the fourth time in the event's six-year history. The award goes to the contract research organization that best demonstrates an ongoing commitment to improving clinical research services in Asia and reducing lead times for customers.
Q: 63.32 (-1.70)
Quintiles Named as a 2016 World's Most Ethical Company by the Ethisphere Institute
BusinessWire - Mon Mar 07, 5:45AM CST
Quintiles, the world's largest provider of product development and integrated healthcare services, has been recognized by the Ethisphere Institute, a global leader in defining and advancing the standards of ethical business practices, as a 2016 World's Most Ethical Company(R).
Q: 63.32 (-1.70)
Quintiles Introduces Continuous Glucose Monitoring Services to Improve Diabetes Outcomes
BusinessWire - Fri Jun 24, 5:45AM CDT
Quintiles today announced the launch of its new Continuous Glucose Monitoring (CGM) service offering. This new solution combines innovative, wearable technology with Quintiles' deep therapeutic and analytical expertise to help enhance the efficiency and quality of diabetes-focused clinical trials.
Q: 63.32 (-1.70)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces a Class Action has Been Commenced Challenging the Fairness of the Sale of IMS Health Holdings, Inc. to Quintiles Transnational Holdings, Inc. -- IMS
GlobeNewswire - Fri Jun 17, 9:19AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
Quintiles CEO to Present at Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 5:45AM CDT
Quintiles CEO Tom Pike will present at the Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 in New York City at the Grand Hyatt New York.
Q: 63.32 (-1.70)
Why These Stocks are Under the Investor Community's Microscope? - Bruker, Quintiles Transnational Holdings, iKang Healthcare Group, and TrovaGene
PR Newswire - Wed Jun 01, 7:20AM CDT
In today's pre-market research, ActiveWallSt.com has selected the following Medical Laboratories and Research stocks for your evaluation: Bruker Corp. (NASDAQ: BRKR), Quintiles Transnational Holdings Inc. (NYSE: Q), iKang Healthcare Group Inc. (NASDAQ: KANG), and TrovaGene Inc. (NASDAQ: TROV). Access these equities free technical alerts at:
Q: 63.32 (-1.70), TROV: 4.55 (-0.25), KANG: 18.98 (-0.31), BRKR: 22.90 (-1.50)
Quintiles Introduces Precision Enrollment to Enhance Patient Recruitment in Oncology Trials
BusinessWire - Tue May 31, 5:45AM CDT
Quintiles, the world's largest provider of product development and integrated healthcare services, today announced its Precision Enrollment offering. The new enrollment model is designed to significantly accelerate site start-up and patient recruitment in oncology clinical trials working with the company's network of investigative sites across the U.S and leveraging secondary data (e.g. electronic health records-EHRs.) In this new model, the traditional site start-up pathway is realigned so a site is only opened after a patient is identified.
Q: 63.32 (-1.70)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of IMS Health Holdings, Inc. to Quintiles Transnational Holdings, Inc.
BusinessWire - Thu May 26, 2:06PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Into the Fairness of the Sale of IMS Health Holdings, Inc. to Quintiles Transnational Holdings, Inc.
BusinessWire - Mon May 23, 4:04PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
IMS HEALTH HOLDINGS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Quintiles Transnational Holdings, Inc.
BusinessWire - Thu May 05, 10:00AM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of IMS Health Holdings, Inc. ("IMS"
(NYSE: IMS) concerning the sale to Quintiles Transnational Holdings, Inc. (NYSE: Q). Under the terms of the agreement, IMS shareholders will only receive 0.3840 Quintiles shares for each IMS share owned. Based on the closing price of Quintiles before the deal was announced, the consideration is valued at $26.53 per share, which is virtually no premium over the 52-week high and lower than at least one analyst's estimated value of $35.00 per share. IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
IMS HEALTH HOLDINGS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
BusinessWire - Wed May 04, 3:40PM CDT
Rigrodsky & Long, P.A.:
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation as to Whether the Sale of IMS Health Holdings, Inc. to Quintiles Transnational Holdings, Inc. is Fair to Shareholders -- IMS
PR Newswire - Wed May 04, 10:54AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
IMS Health and Quintiles merging in $9 billion stock deal
AP - Tue May 03, 2:26PM CDT
NEW YORK (AP) — Health care data company IMS Health and Quintiles, which helps drug companies with clinical trial research, said Tuesday they are merging in an all-stock deal worth nearly $9 billion.
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
Robbins Arroyo LLP: Combination of IMS Health Holdings, Inc. (IMS) with Quintiles Transnational Holdings Inc. (Q) May Not Be in Shareholders' Best Interests
BusinessWire - Tue May 03, 2:15PM CDT
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed combination of IMS Health Holdings, Inc. (NYSE: IMS) with Quintiles Transnational Holdings Inc. (NYSE: Q). On May 3, 2016, the two companies announced the signing of a definitive merger agreement pursuant to which Quintiles will merge with IMS in an all-stock merger of equals transaction. Under the terms of the agreement, IMS shareholders will receive 0.384 shares of Quintiles for each share of IMS they own, the value of which is equivalent to $26.53 per share of IMS.
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
IMS Health and Quintiles to Merge; Quintiles IMS to Become Industry-Leading Information and Technology-Enabled Healthcare Service Provider
BusinessWire - Tue May 03, 5:00AM CDT
--Broad range of healthcare information, technology and services solutions to drive efficiencies and insights across the entire life sciences product lifecycle, from R&D through commercial execution to real-world patient outcomes.
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
IMS Health and Quintiles to Merge
BusinessWire - Tue May 03, 5:00AM CDT
--All-Stock Transaction with Combined 2015 Revenue of $7.2 Billion and Combined Equity Market Capitalization of $17.6 Billion
IMS: 24.59 (-0.64), Q: 63.32 (-1.70)
Novogen Provides Update On Development Of Cantrixil
PR Newswire - Mon May 02, 6:00AM CDT
US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: NVGN) today provided an update on progress regarding the development of Cantrixil (TRXE-002-1), its lead superbenzopyran (SBP) molecule, which is intended for the treatment of ovarian cancer.
Q: 63.32 (-1.70), NVGN: 1.92 (-0.07)
Quintiles Receives Technology Security Award from IDG's CSO Magazine for Fourth Consecutive Year
BusinessWire - Fri Apr 22, 5:45AM CDT
Quintiles, the world's leading provider of biopharmaceutical services, announced today that it has been named to the 2016 CSO50 by IDG's CSO magazine. This award recognizes the company's innovative identity management solution designed to expedite activities related to the delivery of clinical trials while simultaneously protecting confidential user data. This is the company's fourth consecutive year receiving the prestigious security award.
Q: 63.32 (-1.70)
Quintiles' First Quarter 2016 Earnings Call Scheduled for Tuesday, May 3rd
BusinessWire - Mon Apr 18, 4:00PM CDT
Quintiles Transnational Holdings Inc. (NYSE: Q) will release its first quarter 2016 financial results Tuesday, May 3, 2016 prior to its quarterly earnings call at 8:00 a.m. EDT.
Q: 63.32 (-1.70)
Quintiles Honored as 'Best CRO in Asia' for Fourth Time in Six Years
BusinessWire - Wed Mar 23, 6:00PM CDT
Quintiles last night was named the "Best CRO in Asia" at the 2016 BioPharma Asia Industry Awards, winning the honor for the fourth time in the event's six-year history. The award goes to the contract research organization that best demonstrates an ongoing commitment to improving clinical research services in Asia and reducing lead times for customers.
Q: 63.32 (-1.70)
Quintiles Named as a 2016 World's Most Ethical Company by the Ethisphere Institute
BusinessWire - Mon Mar 07, 5:45AM CST
Quintiles, the world's largest provider of product development and integrated healthcare services, has been recognized by the Ethisphere Institute, a global leader in defining and advancing the standards of ethical business practices, as a 2016 World's Most Ethical Company(R).
Q: 63.32 (-1.70)
